Clinical trialsCompany release

Whitehawk starts US Phase 1 of SEZ6-targeting ADC HWK-206 with Fast Track status

🇺🇸 Whitehawk Therapeutics, Inc. (WHWK) · Mon 09 Nov 2026

Whitehawk Therapeutics said its biparatopic antibody drug conjugate for small-cell lung cancer has entered a US Phase 1 trial, as it reported Q3 2026 results with $169.7 million in cash.

Whitehawk Therapeutics reported its third-quarter 2026 results on 9 November and said it has begun a Phase 1 trial in the US of HWK-206, a biparatopic antibody drug conjugate (ADC) directed at SEZ6. The candidate is being developed for small-cell lung cancer and other neuroendocrine tumours.

HWK-206 has been granted Fast Track designation by the US Food and Drug Administration. As general context, Fast Track is intended to speed the development and review of drugs for serious conditions with unmet medical need, and allows more frequent interaction with the agency.

The company has also filed an investigational new drug (IND) application in China for HWK-206. The summary of the results does not give details on trial size, dosing or timelines for the HWK-206 study.

Whitehawk expects to release first Phase 1 data for two other programmes, HWK-007 and HWK-016, in the first half of 2027.

On the financial side, the company posted a net loss of $21.2 million for the quarter and held $169.7 million in cash. The headline of the company's announcement says this funds operations into the second half of 2028.

What it means for your team

  • Fast Track status for HWK-206 signals scope for more frequent FDA dialogue and, if criteria are met, rolling review of a future application.
  • The China IND filing points to a parallel development path in the US and China, which regulatory teams tracking global ADC trials may wish to note.
  • Data from HWK-007 and HWK-016 in 1H 2027 are the next clinical readouts to watch for the company's pipeline.
  • The stated cash runway into 2H 2028 suggests the company expects to fund its early-phase programmes through the next stages of development.

Company's press release (SEC filing): Whitehawk Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Whitehawk Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →